Glucose-6-phosphate dehydrogenase deficiency and the risk of malaria and other diseases in children in Kenya: a case-control and a cohort study
- PMID: 26686045
- PMCID: PMC4703047
- DOI: 10.1016/S2352-3026(15)00152-0
Glucose-6-phosphate dehydrogenase deficiency and the risk of malaria and other diseases in children in Kenya: a case-control and a cohort study
Abstract
Background: The global prevalence of X-linked glucose-6-phosphate dehydrogenase (G6PD) deficiency is thought to be a result of selection by malaria, but epidemiological studies have yielded confusing results. We investigated the relationships between G6PD deficiency and both malaria and non-malarial illnesses among children in Kenya.
Methods: We did this study in Kilifi County, Kenya, where the G6PD c.202T allele is the only significant cause of G6PD deficiency. We tested the associations between G6PD deficiency and severe and complicated Plasmodium falciparum malaria through a case-control study of 2220 case and 3940 control children. Cases were children aged younger than 14 years, who visited the high dependency ward of Kilifi County Hospital with severe malaria between March 1, 1998, and Feb 28, 2010. Controls were children aged between 3-12 months who were born within the same study area between August 2006, and September 2010. We assessed the association between G6PD deficiency and both uncomplicated malaria and other common diseases of childhood in a cohort study of 752 children aged younger than 10 years. Participants of this study were recruited from a representative sample of households within the Ngerenya and Chonyi areas of Kilifi County between Aug 1, 1998, and July 31, 2001. The primary outcome measure for the case-control study was the odds ratio for hospital admission with severe malaria (computed by logistic regression) while for the cohort study it was the incidence rate ratio for uncomplicated malaria and non-malaria illnesses (computed by Poisson regression), by G6PD deficiency category.
Findings: 2863 (73%) children in the control group versus 1643 (74%) in the case group had the G6PD normal genotype, 639 (16%) versus 306 (14%) were girls heterozygous for G6PD c.202T, and 438 (11%) versus 271 (12%) children were either homozygous girls or hemizygous boys. Compared with boys and girls without G6PD deficiency, we found significant protection from severe malaria (odds ratio [OR] 0·82, 95% CI 0·70-0·97; p=0·020) among G6PD c.202T heterozygous girls but no evidence for protection among G6PD c.202T hemizygous boys and homozygous girls (OR 1·18, 0·99-1·40; p=0·056). Median follow-up for the mild disease cohort study was 2·24 years (IQR 2·22-2·85). G6PD c.202T had no effect on other common diseases of childhood in heterozygous girls (incidence rate ratio 0·98, 95% CI 0·86-1·11; p=0·82) or homozygous girls or hemizygous boys (0·93, 0·82-1·04; p=0·25), with the sole exception of a marginally significant increase in the incidence of helminth infections among heterozygous girls.
Interpretation: Heterozygous girls might be the driving force for the positive selection of G6PD deficiency alleles. Further studies are needed to definitively establish the mechanisms by which G6PD deficiency confers an advantage against malaria in heterozygous individuals. Such studies could lead to the development of new treatments.
Funding: Wellcome Trust, UK Medical Research Council, European Union, and Foundation for the National Institutes of Health (as part of the Bill & Melinda Gates Grand Challenges in Global Health Initiative).
Copyright © 2015 Uyoga et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved.
Comment in
-
G6PD deficiency: a polymorphism balanced by heterozygote advantage against malaria.Lancet Haematol. 2015 Oct;2(10):e400-1. doi: 10.1016/S2352-3026(15)00191-X. Epub 2015 Sep 22. Lancet Haematol. 2015. PMID: 26686037 No abstract available.
Similar articles
-
Glucose-6-phosphate dehydrogenase deficiency and susceptibility to childhood diseases in Kilifi, Kenya.Blood Adv. 2020 Dec 8;4(23):5942-5950. doi: 10.1182/bloodadvances.2020003015. Blood Adv. 2020. PMID: 33275767 Free PMC article.
-
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trial.Lancet Infect Dis. 2023 Apr;23(4):471-483. doi: 10.1016/S1473-3099(22)00658-2. Epub 2022 Nov 30. Lancet Infect Dis. 2023. PMID: 36462528 Clinical Trial.
-
X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria.PLoS Med. 2007 Mar;4(3):e66. doi: 10.1371/journal.pmed.0040066. PLoS Med. 2007. PMID: 17355169 Free PMC article.
-
Association of glucose-6-phosphate dehydrogenase deficiency and malaria: a systematic review and meta-analysis.Sci Rep. 2017 Apr 6;7:45963. doi: 10.1038/srep45963. Sci Rep. 2017. PMID: 28382932 Free PMC article. Review.
-
Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women.J Histochem Cytochem. 2009 Nov;57(11):1003-11. doi: 10.1369/jhc.2009.953828. Epub 2009 Jun 22. J Histochem Cytochem. 2009. PMID: 19546473 Free PMC article. Review.
Cited by
-
Glucose-6-phosphate dehydrogenase mutations in malaria endemic area of Thailand by multiplexed high-resolution melting curve analysis.Malar J. 2021 Apr 20;20(1):194. doi: 10.1186/s12936-021-03731-0. Malar J. 2021. PMID: 33879156 Free PMC article.
-
Cerebral Malaria: Current Clinical and Immunological Aspects.Front Immunol. 2022 Apr 20;13:863568. doi: 10.3389/fimmu.2022.863568. eCollection 2022. Front Immunol. 2022. PMID: 35514965 Free PMC article. Review.
-
Nanomedicines for Malaria Chemotherapy: Encapsulation vs. Polymer Therapeutics.Pharm Res. 2018 Oct 15;35(12):237. doi: 10.1007/s11095-018-2517-z. Pharm Res. 2018. PMID: 30324329 Review.
-
Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.Am J Hematol. 2018 Aug;93(4):537-545. doi: 10.1002/ajh.25034. Epub 2018 Jan 27. Am J Hematol. 2018. PMID: 29318647 Free PMC article. Clinical Trial.
-
Predictors of outcome in childhood Plasmodium falciparum malaria.Virulence. 2020 Dec;11(1):199-221. doi: 10.1080/21505594.2020.1726570. Virulence. 2020. PMID: 32063099 Free PMC article. Review.
References
-
- Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371:64–74. - PubMed
-
- Minucci A, Moradkhani K, Hwang MJ. Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review of the ‘old’ and update of the new mutations. Blood Cells Mol Dis. 2012;48:154–165. - PubMed
-
- Ruwende C, Hill A. Glucose-6-phosphate dehydrogenase deficiency and malaria. J Mol Med. 1998;76:581–588. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
